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Abstract
Background: To investigate the relation between maternal thyroid function and the outcome of external cephalic
version (ECV) in breech presentation.
Methods: Prospective cohort study in 141 women (≥ 35 weeks gestation) with a singleton fetus in breech. Blood
samples for assessing thyroid function were taken prior to ECV. Main outcome measure was the relation between
maternal thyroid function and ECV outcome indicated by post ECV ultrasound.
Results: ECV success rate was 77/141 (55%), 41/48 (85%) in multipara and 36/93 (39%) in primipara. Women with a
failed ECV attempt had significantly higher TSH concentrations than women with a successful ECV (p < 0.001).
Multiple logistic regression showed that TSH (OR: 0.52, 95% CI: 0.30-0.90), nulliparity (OR: 0.11, 95% CI: 0.03-0.36),
frank breech (OR: 0.30, 95% CI: 0.10-0.93) and placenta anterior (OR: 0.31, 95% CI: 0.11-0.85) were independently
related to ECV success.
Conclusions: Higher TSH levels increase the risk of ECV failure.
Trial registration number: ClinicalTrials.gov: NCT00516555
Background
The incidence of breech presentation decreases with
increasing gestational age from approximately 16% at
32 weeks to 3-5% of all pregnancies at term [1]. External
cephalic version (ECV) is recommended by the Ameri-
can College of Obstetricians and Gynecologists (ACOG)
and the Royal College of Obstetricians and Gynaecolo-
gists (RCOG) as the best method to reduce the number
of breech presentations and breech deliveries at term
[2,3]. Also the Dutch Obstetrics & Gynaecology Society
h a sp r o m o t e dE C Vb u tu pu n t i ln o w ,t h ei m p l e m e n t a -
tion of this guideline is rather poor and a recent study
has been started to evaluate possible barriers [4].
Reported success rates vary widely from 30-80% [3].
Several factors have been associated with successful
ECV outcome including parity, type of breech, placenta
location, amniotic fluid index, and engagement of the
breech [5-7].
Recently, our research group showed that at 36 weeks
gestation women with TSH levels above 2.5 mIU/l are at
risk for breech presentation [8,9]. It is stated that fetal
movements and mobility are a prerequisite for sponta-
neous version into the cephalic position [10]. Since
maternal thyroid function is related to the probability of
spontaneous cephalic presentation, it may be hypothe-
sized that TSH may, also, affect ECV outcome [8,9].
To the best of our knowledge, this is the first prospec-
tive study to examine the relationship between maternal
thyroid hormone status and ECV success.
Methods
Participants
Over a period of two years, 194 women were prospec-
tively seen in a specialized ECV outpatient clinic
and invited to participate when they presented at ≥
35 weeks gestation with a fetus in breech presentation.
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the Dutch language were eligible (n = 169). Nineteen
patients declined to participate, while four patients with
a transverse lie and five patients with known thyroid
disease were excluded. Data analysis, therefore, included
the remaining 141 participants (see Table 1), all of
whom gave written informed consent.
This study was approved by the Medical Ethical Com-
mittee of the Catharina Hospital in Eindhoven, the
Netherlands.
Assessments
At intake, demographic features (maternal age, BMI,
tobacco/alcohol use) and obstetrical parameters (parity,
previous obstetrical history) were recorded. Prior to
ECV, ultrasound was performed to determine type of
breech, amniotic fluid index and placental location.
Ultrasound was repeated post-ECV in order to confirm
success. At birth, fetal presentation, placental and birth
weight were carefully assessed.
ECV intervention
Cardiotocography was performed routinely before and
after the procedure. Before ECV, all women had a full
bladder and were routinely given a tocolytic drug (Atosi-
ban, 6.75 mg. intravenously). Anti-D (1000 IE) was given
prophylactically to all Rhesus negative women. ECV
(monitored by ongoing ultrasound) was performed by
two experienced obstetricians working in unison: the
hands of one staff member concentrated on the breech,
while the other’s concentrated on the fetal head, with
manipulation being consecutive rather than simulta-
neous (see Additional file 1). While a “forward somer-
sault” was the preferred method to achieve cephalic
position, a “backward flip” was an alternative strategy
for nulliparous patients with a frank breech presenta-
tion. ECV was defined as successful when cephalic posi-
tion was demonstrated on the post-ECV ultrasound.
Thyroid parameters
Blood samples were taken prior to administration of the
tocolytic drug and subsequently stored for assessing the
following thyroid parameters: thyroxine (FT4), thyrotro-
phin (TSH) and thyroid peroxidase antibodies (TPO-Ab).
TSH was measured using a solid-phase, two-site chemi-
luminescent enzyme immunometric assay (IMMULITE
Third generation TSH, Diagnostic Products Corporation,
Los Angeles USA). The inter-assay coefficients of varia-
tion were 5.0% and 4.4% at concentrations 0.22 mIU/l
and 2.9 mIU/l, respectively. FT4 concentration was also
measured by means of a solid-phase immunometric assay
(IMMULITE Free T4). The inter-assay coefficients of
variation for this technique were 6.7% and 4.4% at con-
centrations of 11.6 pmol/l and 31.5 pmol/l, respectively.
Reference ranges for non-pregnant women for TSH and
FT4 were: 0.4 - 4.0 mIU/l and 10 - 24 pmol/l, respec-
tively. The IMMULITE TPO-Ab kit was used for the
determination of antibodies against thyroid peroxidase
(TPO). The inter-assay coefficients of variation for this
analysis were 9% and 9.5% for concentrations of 40 kU/l
Table 1 Characteristics and thyroid parameters of 141
breech women who had an ECV attempt
Mean (SD) N (%)
Demographic features
Maternal age (years) 31.6 (4.2)
Range (23 - 46)
Any tobacco use 11 (8)
Any alcohol use 12 (8.5)
Body mass index (BMI)
Range (17 - 47) 23.7 (4.2)
BMI < 25 112 (79.5)
BMI between 25 and 30 17 (12)
BMI > 30 12 (8.5)
Previous miscarriage in life 31 (22)
Obstetrical features
Nulliparity 93 (66)
Multiparity 48 (34)
Gestational age at ECV (wks) 36.1 (0.9)
Range (35.0-39.9)
Type of breech
Frank 93 (66)
Complete 36 (25.5)
Incomplete 12 (8.5)
Placenta location
Anterior 55 (39)
Posterior 56 (40)
Lateral 30 (21)
Cephalic presentation after ECV 77 (55)
Cephalic presentation at delivery 79 (56)
Placental weight (grams) 615 (127)
Range (295 - 1000)
Birth weight (grams) 3344 (447)
Range (1765 - 4576)
Thyroid parameters
TSH mIU/l
median 1.48
Range (0.02 - 10.0)
FT4 pmol/l
median 10.0
Range (7.1 - 14.0)
TPO-Ab > 35 kU/l 9 (6)
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dardized in terms of the International Reference Prepara-
tion for anti-TPO MRC 66/387. TPO-Ab concentrations
>3 5k U / la t3 6w e e k sg e s t a t i o nw e r er e g a r d e da sa n t i -
body positive.
Statistical analysis
Statistical analysis was performed using the Statistical
Package for the Social Sciences (SPSS 17.0). Initial ana-
lyses described the sample using means, standard devia-
tions and frequencies. The distributions of FT4 and
TSH were non-Gaussian (Kolmogorov-Smirnov tests);
therefore, Mann-Whitney U-tests were used to examine
FT4 and TSH for group comparisons and ECV success.
Associations among elevated maternal thyroid antibodies
(TPO-Ab > 35 kU/l) and ECV outcome were analyzed
using chi-square tests. Prevalence of successful ECV
stratified according to quartiles of TSH was also exam-
ined using a chi-square test. Single and multiple logistic
regression analysis (odds ratios and 95% CI’s) were per-
formed to calculate un-adjusted and adjusted ORs for
successful ECV (dependent variable). The independent
variable was TSH. For the multiple logistic regression
analysis, age (continuous), body mass index (continu-
ous), parity (dichotomized in nulliparous and parous),
type of breech (frank breech versus the rest), gestational
age at version (continuous), placental position (dichoto-
mized in anterior versus other), placental weight (con-
tinuous), birth weight (continuous) and amniotic fluid
index (dichotomized using 10 cm as a cutoff) were also
controlled for.
Results
The overall ECV success rate, indicated by the post-
procedure ultrasound results, was 55% (77/141), and
was significantly lower in nulliparous women (39%:
36/93) than in multiparous women (85%: 41/48; c
2 =
27, df = 1, p < 0.001). In one patient prolonged post-
ECV fetal bradycardia occurred which necessitated
emergency cesarean section. Transient heart rate
abnormalities were observed in 3 patients. Spontaneous
version into cephalic position at birth after failed ECV
occurred in 2 (nulliparous) women. Spontaneous version
back into breech after successful ECV did not occur.
The median TSH level for the whole study sample was
1.48 mIU/l (range: 0.02 - 10 mIU/l). Table 2 shows the
distribution of FT4 and TSH values in relation to ECV
outcome. Women with failed ECV’s had significantly
higher TSH levels than those with successful ECV’s
(Mann-Whitney U, p < 0.001), but corresponding
FT4 levels did not differ between groups (Mann-Whit-
ney U, p = 0.88). The correlation between FT4 and TSH
was 0.18, (p = 0.034). Also, the prevalence of elevated
TPO-Ab (> 35 kU/l) did not differ between groups (9%
versus 4%, p = 0.18) with regard to ECV outcome.
F i g u r e1s h o w st h ep r e v a l e n c eo fs u c c e s s f u lE C V
according to different TSH quartiles (25
th percentile: <
0.99 mIU/l, 25
th -5 0
th percentile: 0.99 - 1.48 mIU/l,
50
th -7 5
th percentile: 1.49 - 2.0 mIU/l and > 75
th per-
centile: > 2.0 mIU/l). Clearly, the percentage of ECV
success significantly decreased with increasing TSH
quartile (74% to 30%, c
2 = 15, df = 3, p = 0.002).
I nT a b l e3 ,s i n g l el o g i s t i cr e g r e s s i o ni ss h o w nw i t h
successful ECV as the dependent variable. TSH, parity,
type of breech and placenta anterior location were all
significantly related to successful ECV outcome. In
Table 3, adjusted OR’s are shown with TSH as indepen-
dent variable and successful ECV as dependent variable
using multiple logistic regression analysis. TSH (OR:
0.52, 95% CI: 0.30-0.90), nulliparity (OR: 0.11, 95% CI:
0.03-0.36), frank breech (OR: 0.30, 95% CI: 0.10-0.93)
and placenta anterior (OR: 0.31, 95% CI: 0.11-0.85) were
all significantly and independently related to ECV
success.
In healthy pregnant women (without elevated concen-
trations of TPO-Ab and with proven sufficient iodine
intake) trimester specific cutoffs for elevated TSH are
still lacking. A frequently used upper TSH reference
level in pregnancy is ≥ 2.5 mIU/l [11]. In the current
study 20 women had a TSH above this level. Of these
20 women 5 (25%) underwent successful ECV, com-
pared to 72 successful ECVs from the sample of
121 women (60%) with TSH levels below the cutoff of
2.5 mIU/l (c
2 = 8.2, df = 1, p = 0.004). The RR of
women in breech with TSH above 2.5 mIU/l for failed
ECV was 2.4, (95% CI = 1.1 - 5.3).
Discussion
In the current study, successful ECV outcome was inde-
pendently related to maternal TSH: women with unsuc-
cessful ECV had significantly higher TSH levels.
The ECV success rate of 55% in the current study is
comparable to others reported in the literature [2,3].
While our data support earlier observations showing
that factors affecting ECV success include parity, type of
breech and placenta location, to our knowledge, this is
t h ef i r s ts t u d yr e p o r t i n go nap o s s i b l er e l a t i o n s h i p
between maternal thyroid function and ECV outcome
[5-7].
W er e c e n t l ys h o w e di nal a r g es a m p l eo fo v e r
1000 pregnant women from the general population that
higher levels of TSH constitutes a risk factor for breech
presentation [8].
How can the observed relationship between maternal
TSH and ECV outcome be explained? Several mechan-
isms might be suggested. First, one could argue that
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tion, thereby negatively affecting ECV outcome. Empiri-
cal evidence regarding such a direct effect is, however,
scarce. TSH receptors have been shown in other non-
thyroid tissues such as bone, heart and brain tissue, but
so far no studies on human uterine samples have been
published [12,13]. Also, in patients with subclinical
hypothyroidism (reflected by high TSH), the myocytes
of the smooth muscle cells of the aorta are dysfunc-
tional, leading to increased arterial stiffness and
impaired diastolic function [14]. The mechanism behind
is a reduced activity of the sarcoplasmatic reticulum
CA-ATPase which controls the efficient concentration
of calcium in the cytoplasm. Another study in sub-
clinical hypothyroid women showed a beneficial effect of
thyroxine replacement on arterial stiffness [15]. It is
known from earlier studies that thyroid hormone (T3)
has a direct relaxation effect on vascular smooth muscle
cells [16]. It might be hypothesized that a similar rela-
tion between TSH and uterine myocytes does exist.
Inappropriate relaxation of uterine smooth muscle ves-
sels in women with high TSH might hinder ECV.
Another candidate mechanism might relate to fetal
motility and its ability to facilitate spontaneous version.
High maternal TSH during gestation has been asso-
ciated with impaired neonatal motor function [17]. One
may argue that higher levels of maternal TSH could
conceivably reflect low circulating fetal T4 levels. Short-
age of fetal T4 compromises fetal neural maturation
and, in turn, fetal motility through its effects on muscle
tone and reflexes [18]. Furthermore, breech babies tend
to be smaller, have lower scores on neuromotor tests,
and are balanced-impaired until the age of 12-18 months
[19-22]. Their impaired neuromotor development could
Figure 1 Percentage of ECV success in relation to TSH quartiles (mIU/l) in 141 women with breech presentation ≥ 35 weeks gestation.
Table 2 Thyroid parameters in 141 breech women in relation to ECV outcome
Success ECV
N=7 7
Failed ECV
N=6 4
P
Mann-
Whitney U
P
c
2 (df = 1)
Median TSH mIU/l 1.20 1.90 < 0.001
Range 0.02-10.0 0.60-9.20
Median FT4 pmol/l 10.0 10.0 0.88
Range 7.2-14.0 7.1-14.2
TPO-Ab > 35 kU/l 3 (4%) 6 (9%) 0.18
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poor fetal movements result in less expanded intra-uter-
ine environment which is needed for successful ECV.
The current study findings did not reveal differences
in FT4 level between the successful versus the unsuc-
cessful ECV groups. This may have been due to the
greater sensitivity of TSH - compared to FT4 - to detect
small changes in the set point of the hypothalamus-
pituitary-thyroid axis [23]. Moreover, it has been
reported that pregnancy FT4 assessments are less reli-
able than non-pregnancy assessments [24]. Also in this
study a weak correlation (r = 0.18, p = 0.34) was found
between FT4 and TSH, but in the opposite direction of
what would be expected: normally there is an inverse
correlation between TSH and FT4.
Despite growing insight into the prognostic factors of
successful ECV, no scoring system that accurately pre-
dicts success exists [25-28]. It may well be that the
inclusion of maternal TSH would lead to enhanced
probability-of-ECV success estimates.
A limitation of the current study relates to the fact
that iodine excretion data in mothers and neonates were
not assessed. This made it impossible to relate higher
TSH levels to inadequate iodine intake during gestation.
Also cord blood was not assessed and therefore fetal
TSH and T4 levels could not be taken into account.
A major strength of the current study was its relatively
l a r g es a m p l es i z ea n dt h ef a c tt h a tE C Vw a sp e r f o r m e d
in one obstetric department by a small team of trained
experts following the same protocol and blind to the
thyroid status of the patients.
Conclusions
In conclusion, the current study is among the first to
report a possible relationship between maternal thyroid
function and ECV outcome. While the study suggests
that higher levels of TSH are independently related to
ECV outcome, the precise mechanism behind this find-
ing remains to be determined.
Additional material
Additional file 1: ECV technique. ECV is performed by two experienced
obstetricians working closely thogether: the hands of one obstetrician
concentrate on the breech, while the other’s concentrate on the fetal
head, with manipulation being consecutive rather than simultaneous and
changing from a “pull"movement into a “push"movement. The procedure
is monitored by a third person by ongoing ultrasound.
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